AbbVie and Ichnos Glenmark Innovation (IGI) have announced an exclusive licensing agreement for ISB 2001, a trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma. This partnership grants AbbVie the rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China.
"Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously," said Roopal Thakkar, M.D., executive vice president of research and development and chief scientific officer at AbbVie. "This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma."
Cyril Konto, M.D., President and CEO of IGI, stated: "ISB 2001 exemplifies the potential of our BEAT protein platform to generate effective multispecifics that may overcome resistance and improve outcomes in hard-to-treat cancers."
Under this agreement, IGI will receive an upfront payment of $700 million from AbbVie and is eligible for up to $1.225 billion in milestone payments as well as tiered royalties on net sales.
ISB 2001 targets BCMA and CD38 on myeloma cells and CD3 on T cells. Recent data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed a sustained overall response rate of 79% among patients.
The U.S. Food & Drug Administration granted ISB 2001 Orphan Drug Designation in July 2023 and Fast Track Designation in May 2025.
For further details about AbbVie's oncology efforts or the BEAT Multispecific Platform used by IGI to develop ISB 2001, visit their respective websites.